|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DEDD2 |
Gene summary for DEDD2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DEDD2 | Gene ID | 162989 |
| Gene name | death effector domain containing 2 | |
| Gene Alias | FLAME-3 | |
| Cytomap | 19q13.2 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q8WXF8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 162989 | DEDD2 | C57 | Human | Oral cavity | OSCC | 1.45e-41 | 1.50e+00 | 0.1679 |
| 162989 | DEDD2 | C06 | Human | Oral cavity | OSCC | 9.54e-08 | 1.35e+00 | 0.2699 |
| 162989 | DEDD2 | C08 | Human | Oral cavity | OSCC | 1.51e-20 | 6.09e-01 | 0.1919 |
| 162989 | DEDD2 | C09 | Human | Oral cavity | OSCC | 1.61e-14 | 5.56e-01 | 0.1431 |
| 162989 | DEDD2 | LN22 | Human | Oral cavity | OSCC | 1.39e-08 | 1.18e+00 | 0.1733 |
| 162989 | DEDD2 | LN46 | Human | Oral cavity | OSCC | 2.92e-15 | 7.17e-01 | 0.1666 |
| 162989 | DEDD2 | LP15 | Human | Oral cavity | LP | 4.57e-07 | 1.45e+00 | 0.2174 |
| 162989 | DEDD2 | SYSMH1 | Human | Oral cavity | OSCC | 2.30e-09 | 3.65e-01 | 0.1127 |
| 162989 | DEDD2 | SYSMH2 | Human | Oral cavity | OSCC | 1.36e-14 | 6.36e-01 | 0.2326 |
| 162989 | DEDD2 | SYSMH3 | Human | Oral cavity | OSCC | 7.80e-14 | 4.73e-01 | 0.2442 |
| 162989 | DEDD2 | SYSMH4 | Human | Oral cavity | OSCC | 7.77e-08 | 2.73e-01 | 0.1226 |
| 162989 | DEDD2 | SYSMH5 | Human | Oral cavity | OSCC | 8.17e-03 | 1.85e-01 | 0.0647 |
| 162989 | DEDD2 | SYSMH6 | Human | Oral cavity | OSCC | 1.31e-18 | 3.88e-01 | 0.1275 |
| 162989 | DEDD2 | GSM5252137_BPH556PrGA2_Fcol | Human | Prostate | BPH | 3.02e-05 | 4.89e-01 | -0.23 |
| 162989 | DEDD2 | 047563_1562-all-cells | Human | Prostate | BPH | 1.04e-03 | -1.42e-01 | 0.0791 |
| 162989 | DEDD2 | Dong_P1 | Human | Prostate | Tumor | 1.60e-25 | 1.90e-01 | 0.035 |
| 162989 | DEDD2 | Dong_P3 | Human | Prostate | Tumor | 4.69e-16 | 2.32e-01 | 0.0278 |
| 162989 | DEDD2 | Dong_P4 | Human | Prostate | Tumor | 7.36e-03 | 7.32e-03 | 0.0292 |
| 162989 | DEDD2 | Dong_P5 | Human | Prostate | Tumor | 4.98e-45 | 5.02e-01 | 0.053 |
| 162989 | DEDD2 | GSM5353224_PA_PR5186_Pool_1_2_3_S27_L001 | Human | Prostate | Tumor | 2.30e-02 | 4.03e-01 | 0.1621 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:200123327 | Esophagus | HGIN | regulation of apoptotic signaling pathway | 97/2587 | 356/18723 | 1.36e-11 | 1.57e-09 | 97 |
| GO:001607219 | Esophagus | HGIN | rRNA metabolic process | 72/2587 | 236/18723 | 2.26e-11 | 2.56e-09 | 72 |
| GO:000640120 | Esophagus | HGIN | RNA catabolic process | 77/2587 | 278/18723 | 7.63e-10 | 6.36e-08 | 77 |
| GO:003465519 | Esophagus | HGIN | nucleobase-containing compound catabolic process | 98/2587 | 407/18723 | 1.44e-08 | 8.94e-07 | 98 |
| GO:004670017 | Esophagus | HGIN | heterocycle catabolic process | 103/2587 | 445/18723 | 5.44e-08 | 2.99e-06 | 103 |
| GO:200123519 | Esophagus | HGIN | positive regulation of apoptotic signaling pathway | 41/2587 | 126/18723 | 6.06e-08 | 3.22e-06 | 41 |
| GO:002241120 | Esophagus | HGIN | cellular component disassembly | 102/2587 | 443/18723 | 8.31e-08 | 4.33e-06 | 102 |
| GO:004427018 | Esophagus | HGIN | cellular nitrogen compound catabolic process | 103/2587 | 451/18723 | 1.10e-07 | 5.56e-06 | 103 |
| GO:001943917 | Esophagus | HGIN | aromatic compound catabolic process | 105/2587 | 467/18723 | 1.89e-07 | 9.31e-06 | 105 |
| GO:190136117 | Esophagus | HGIN | organic cyclic compound catabolic process | 106/2587 | 495/18723 | 1.94e-06 | 7.13e-05 | 106 |
| GO:00346606 | Esophagus | HGIN | ncRNA metabolic process | 104/2587 | 485/18723 | 2.26e-06 | 8.23e-05 | 104 |
| GO:009719126 | Esophagus | HGIN | extrinsic apoptotic signaling pathway | 56/2587 | 219/18723 | 2.48e-06 | 8.80e-05 | 56 |
| GO:000862518 | Esophagus | HGIN | extrinsic apoptotic signaling pathway via death domain receptors | 23/2587 | 82/18723 | 5.47e-04 | 7.73e-03 | 23 |
| GO:200123626 | Esophagus | HGIN | regulation of extrinsic apoptotic signaling pathway | 36/2587 | 151/18723 | 6.20e-04 | 8.58e-03 | 36 |
| GO:200123810 | Esophagus | HGIN | positive regulation of extrinsic apoptotic signaling pathway | 15/2587 | 48/18723 | 1.49e-03 | 1.73e-02 | 15 |
| GO:0016072110 | Esophagus | ESCC | rRNA metabolic process | 197/8552 | 236/18723 | 1.31e-33 | 1.18e-30 | 197 |
| GO:003466012 | Esophagus | ESCC | ncRNA metabolic process | 346/8552 | 485/18723 | 4.35e-31 | 2.51e-28 | 346 |
| GO:2001233111 | Esophagus | ESCC | regulation of apoptotic signaling pathway | 256/8552 | 356/18723 | 4.11e-24 | 1.04e-21 | 256 |
| GO:0022411111 | Esophagus | ESCC | cellular component disassembly | 305/8552 | 443/18723 | 1.94e-23 | 4.57e-21 | 305 |
| GO:0006401110 | Esophagus | ESCC | RNA catabolic process | 204/8552 | 278/18723 | 3.39e-21 | 5.66e-19 | 204 |
| Page: 1 2 3 4 5 6 7 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DEDD2 | insertion | Nonsense_Mutation | novel | c.394_395insAAGCAATTCTCCTGCCTCAGCCTCCCAAGTAGCTGGAACTACAG | p.Arg132GlnfsTer11 | p.R132Qfs*11 | Q8WXF8 | protein_coding | TCGA-A8-A09B-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | SD | ||
| DEDD2 | SNV | Missense_Mutation | novel | c.795C>G | p.Asp265Glu | p.D265E | Q8WXF8 | protein_coding | deleterious(0) | benign(0.151) | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| DEDD2 | SNV | Missense_Mutation | rs376459217 | c.881N>A | p.Arg294His | p.R294H | Q8WXF8 | protein_coding | deleterious(0) | possibly_damaging(0.454) | TCGA-AZ-6598-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| DEDD2 | SNV | Missense_Mutation | c.743N>A | p.Val248Asp | p.V248D | Q8WXF8 | protein_coding | deleterious(0) | possibly_damaging(0.796) | TCGA-CM-6676-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| DEDD2 | SNV | Missense_Mutation | rs535277377 | c.398N>A | p.Arg133His | p.R133H | Q8WXF8 | protein_coding | tolerated(0.61) | possibly_damaging(0.865) | TCGA-NH-A5IV-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| DEDD2 | SNV | Missense_Mutation | rs781250383 | c.556N>A | p.Ala186Thr | p.A186T | Q8WXF8 | protein_coding | tolerated(0.57) | benign(0.003) | TCGA-EI-6507-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| DEDD2 | SNV | Missense_Mutation | c.569N>G | p.Ser190Cys | p.S190C | Q8WXF8 | protein_coding | tolerated(0.19) | benign(0.21) | TCGA-A5-A0G5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| DEDD2 | SNV | Missense_Mutation | novel | c.709N>A | p.Ala237Thr | p.A237T | Q8WXF8 | protein_coding | tolerated(1) | benign(0.007) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| DEDD2 | SNV | Missense_Mutation | rs750217130 | c.395G>A | p.Arg132His | p.R132H | Q8WXF8 | protein_coding | tolerated(0.15) | benign(0.007) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| DEDD2 | SNV | Missense_Mutation | rs781250383 | c.556N>A | p.Ala186Thr | p.A186T | Q8WXF8 | protein_coding | tolerated(0.57) | benign(0.003) | TCGA-AJ-A8CW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |